隨著中國(guó)經(jīng)濟(jì)回暖，加之兩會(huì)期間釋放更多令人鼓舞的信號(hào)，更多穩(wěn)健政策出臺(tái)，讓跨國(guó)公司在華發(fā)展信心更堅(jiān)定。拜耳集團(tuán)大中華區(qū)首席財(cái)務(wù)官烏爾里?！に沟俑ケ硎?，憑借龐大的市場(chǎng)規(guī)模、先進(jìn)的工業(yè)體系、強(qiáng)大的供應(yīng)鏈競(jìng)爭(zhēng)力和不斷優(yōu)化的營(yíng)商環(huán)境，中國(guó)市場(chǎng)仍極具吸引力，拜耳等跨國(guó)企業(yè)在中國(guó)拓展業(yè)務(wù)、擴(kuò)大投資的意愿強(qiáng)烈。

China's recovery, along with more encouraging signals and prudent policies introduced during the two sessions, is injecting greater confidence into multinationals operating in China, said a senior executive from Bayer.
拜耳公司一位高管表示，中國(guó)經(jīng)濟(jì)正在復(fù)蘇，加之兩會(huì)期間釋放更多令人鼓舞的信號(hào)，更多穩(wěn)健政策出臺(tái)，讓跨國(guó)公司在華發(fā)展信心更堅(jiān)定。

Ulrich Stefer, chief financial officer of Bayer Group Greater China, said: "China, without any doubt, plays a crucial role in impacting global growth in 2023 as the world's second-largest economy. We noticed that various international financial institutions and investment banks increased their predictions for China's economic growth in 2023."
拜耳集團(tuán)大中華區(qū)首席財(cái)務(wù)官烏爾里奇·史蒂夫表示：“毫無(wú)疑問(wèn)，中國(guó)作為世界第二大經(jīng)濟(jì)體，在影響2023年全球經(jīng)濟(jì)增長(zhǎng)方面發(fā)揮著關(guān)鍵作用。我們注意到，各國(guó)際金融機(jī)構(gòu)和投行都上調(diào)了對(duì)2023年中國(guó)經(jīng)濟(jì)增長(zhǎng)的預(yù)測(cè)?！?/p>

He said that with the massive market size, sophisticated industrial system, strong supply chain competitiveness and the improving business environment, the Chinese market remains extremely attractive on a far-reaching level for multinational companies, including Bayer, to join and expand their investment.
他表示，憑借龐大的市場(chǎng)規(guī)模、先進(jìn)的工業(yè)體系、強(qiáng)大的供應(yīng)鏈競(jìng)爭(zhēng)力和不斷優(yōu)化的營(yíng)商環(huán)境，中國(guó)市場(chǎng)仍極具吸引力，拜耳等跨國(guó)企業(yè)在中國(guó)拓展業(yè)務(wù)、擴(kuò)大投資的意愿強(qiáng)烈。

"The multi-million euros expansion project of Bayer's Beijing Pharmaceuticals plant will be completed this year and it is expected to boost our prescription drug production capacities by 40 percent and largely enhance our capability to meet Chinese patients' medical needs," he said.
史蒂夫稱：“拜耳處方藥北京工廠產(chǎn)能提升項(xiàng)目將于今年完成。該項(xiàng)目投資數(shù)千萬(wàn)歐元，預(yù)計(jì)將使拜耳處方藥生產(chǎn)能力提高40%，并大大提高拜耳滿足中國(guó)患者醫(yī)療需求的能力?！?/p>

Speaking of China's business environment, Stefer said: "Over the years, Bayer has witnessed China's substantial efforts to firmly improve the business environment for all kinds of enterprises."
談到中國(guó)的營(yíng)商環(huán)境，史蒂夫表示：“多年來(lái)，拜耳見(jiàn)證了中國(guó)為堅(jiān)定優(yōu)化各類企業(yè)的營(yíng)商環(huán)境的持續(xù)努力?！?/p>

"Particularly, the Foreign Investment Law and China's free trade zones have optimized China's law-based and open business environment for foreign companies, providing a solid basis for our in-depth participation and investment in this market," he said.
“特別是《中華人民共和國(guó)外商投資法》和自由貿(mào)易區(qū)優(yōu)化法治化營(yíng)商環(huán)境、服務(wù)外資企業(yè)，為拜耳深入?yún)⑴c和投資中國(guó)市場(chǎng)提供了堅(jiān)實(shí)的基礎(chǔ)。”

In 2022, China increased the number of items in the Catalogue of Encouraged Industries for Foreign Investment to 1,474 from 987 in 2017. The number is expected to further increase with the publication of the 2023 catalogue.
今年1月1日正式生效施行的《鼓勵(lì)外商投資產(chǎn)業(yè)目錄（2022年版）》總條目從2017年的987個(gè)增加到1474個(gè)，預(yù)計(jì)條目數(shù)量將進(jìn)一步增加。

"It opens up new areas and industry fields for foreign investment, such as advanced manufacturing, further unleashing the market potential and offering greater opportunities for foreign companies," Stefer said.
史蒂夫表示：“新版《鼓勵(lì)外商投資產(chǎn)業(yè)目錄》使外商投資企業(yè)進(jìn)入的行業(yè)和領(lǐng)域擴(kuò)大到先進(jìn)制造業(yè)等新行業(yè)領(lǐng)域，此舉進(jìn)一步釋放了市場(chǎng)潛力，為外企提供了更多機(jī)會(huì)?！?/p>

Data from the Ministry of Commerce showed that, ever since the Foreign Investment Law took effect in Jan 1 2020, 90 percent of the surveyed foreign enterprises held that the law was implemented well, and China's business environment was optimized.
商務(wù)部數(shù)據(jù)顯示，自《外商投資法》于2020年1月1日生效以來(lái)，九成受訪外企認(rèn)為該法實(shí)施良好，中國(guó)的營(yíng)商環(huán)境得到優(yōu)化。


來(lái)源：中國(guó)日?qǐng)?bào)網(wǎng)
編輯：董靜